Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Multiple Sclerosis

  Free Subscription


22.01.2018

1 Acta Neurol Scand
1 Ann Neurol
2 Arch Phys Med Rehabil
1 BMC Neurol
2 J Neuroimmunol
1 J Neurol
1 Magn Reson Med
3 Mult Scler
1 Nat Rev Neurol
1 Neurologia
2 Neurology
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Neurol Scand

  1. CAMBRON M, Hadhoum N, Duhin E, Lacour A, et al
    JCV serology in time: 3 years of follow-up.
    Acta Neurol Scand. 2017;136:54-58.
    PubMed     Text format     Abstract available


    Ann Neurol

  2. ESHAGHI A, Prados F, Brownlee W, Altmann DR, et al
    Deep grey matter volume loss drives disability worsening in multiple sclerosis.
    Ann Neurol. 2018 Jan 13. doi: 10.1002/ana.25145.
    PubMed     Text format     Abstract available


    Arch Phys Med Rehabil

  3. EHDE DM, Arewasikporn A, Alschuler KN, Hughes AJ, et al
    Moderators Of Treatment Outcomes Following Telehealth Self-Management And Education In Adults With Multiple Sclerosis: A Secondary Analysis Of A Randomized Controlled Trial.
    Arch Phys Med Rehabil. 2018 Jan 11. pii: S0003-9993(18)30007.
    PubMed     Text format     Abstract available

  4. CASEY B, Coote S, Hayes S, Gallagher S, et al
    Changing physical activity behavior in people with Multiple Sclerosis: A Systematic Review and Meta-Analysis.
    Arch Phys Med Rehabil. 2018 Jan 11. pii: S0003-9993(18)30008.
    PubMed     Text format     Abstract available


    BMC Neurol

  5. JAIN V, Arunkumar A, Kingdon C, Lacerda E, et al
    Prevalence of and risk factors for severe cognitive and sleep symptoms in ME/CFS and MS.
    BMC Neurol. 2017;17:117.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  6. OZKUL C, Guclu-Gunduz A, Irkec C, Fidan I, et al
    Effect of combined exercise training on serum brain-derived neurotrophic factor, suppressors of cytokine signaling 1 and 3 in patients with multiple sclerosis.
    J Neuroimmunol. 2018 Jan 3. pii: S0165-5728(17)30484.
    PubMed     Text format     Abstract available

  7. BAULINA N, Kulakova O, Kiselev I, Osmak G, et al
    Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission.
    J Neuroimmunol. 2018 Jan 5. pii: S0165-5728(17)30447.
    PubMed     Text format     Abstract available


    J Neurol

  8. DI GREGORIO M, Gaetani L, Eusebi P, Floridi P, et al
    Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
    J Neurol. 2018 Jan 11. pii: 10.1007/s00415-017-8726.
    PubMed     Text format     Abstract available


    Magn Reson Med

  9. GABR RE, Pednekar AS, Kamali A, Lincoln JA, et al
    Interleaved susceptibility-weighted and FLAIR MRI for imaging lesion-penetrating veins in multiple sclerosis.
    Magn Reson Med. 2018 Jan 15. doi: 10.1002/mrm.27091.
    PubMed     Text format     Abstract available


    Mult Scler

  10. RIMKUS CM, Schoonheim MM, Steenwijk MD, Vrenken H, et al
    Gray matter networks and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650.
    PubMed     Text format     Abstract available

  11. HODEL J, Bapst B, Outteryck O, Verclytte S, et al
    Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Mult Scler. 2018 Jan 1:1352458517750765. doi: 10.1177/1352458517750765.
    PubMed     Text format     Abstract available

  12. BOVE R, Healy BC, Musallam A, Soltany P, et al
    Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.
    Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768.
    PubMed     Text format     Abstract available


    Nat Rev Neurol

  13. TUR C, Moccia M, Barkhof F, Chataway J, et al
    Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.
    Nat Rev Neurol. 2018 Jan 12. pii: nrneurol.2017.
    PubMed     Text format     Abstract available


    Neurologia

  14. ALVAREZ AYUSO L, Rodriguez Marrodan B, Blasco Quilez MR, Garcia-Merino JA, et al
    Economic impact of the new oral treatments for multiple sclerosis.
    Neurologia. 2018 Jan 11. pii: S0213-4853(17)30375.
    PubMed     Text format     Abstract available


    Neurology

  15. PETERSEN ER, Oturai AB, Koch-Henriksen N, Magyari M, et al
    Smoking affects the interferon beta treatment response in multiple sclerosis.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004949.
    PubMed     Text format     Abstract available

  16. SUMOWSKI JF, Benedict R, Enzinger C, Filippi M, et al
    Cognition in multiple sclerosis: State of the field and priorities for the future.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004977.
    PubMed     Text format     Abstract available


    PLoS One

  17. AGAH E, Zardoui A, Saghazadeh A, Ahmadi M, et al
    Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0190252.
    PubMed     Text format     Abstract available

  18. WANG C, Klistorner A, Ly L, Barnett MH, et al
    White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques.
    PLoS One. 2018;13:e0191131.
    PubMed     Text format     Abstract available

  19. LAVTAR P, Rudolf G, Maver A, Hodzic A, et al
    Association of circadian rhythm genes ARNTL/BMAL1 and CLOCK with multiple sclerosis.
    PLoS One. 2018;13:e0190601.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: